Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Neuro Medtech Investors Have Time (And Money) For The Pain

This article was originally published in Start Up

Executive Summary

START-UP reviews five years of fundraising and exit activities for privately held medtech and diagnostics companies developing neurology treatments. Part 2 of our series on neuro-focused capital raising and bow-outs.

You may also be interested in...



OUS Approvals Analysis: Expanded CoreValve Indication And Zika IVDs Among August’s CE Marks

August was another slow month for announcements of medical device approvals outside the US, but the short list of non-US approvals this month includes a broad range of device-types approved, notably a much-awaited expanded indication for Medtronic’s CoreValve Evolut R, in six different territories.

Neuromodulation: Three Start-Ups To Watch

The neuromodulation market is growing at a rapid pace and investors and strategics are paying close attention to early-stage innovators. We highlight Cardionomic, Nuviant and Pixium, three young companies that are listening to the brain, fixing broken hearts and making the blind see.

US Neurostimulation Devices Market Forecast to Grow By $1B+ With New Indications, New Technologies

The US neurostimulation technology market will grow nearly 46% over the next five years, according to a new report from Medtech Insight.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT038006

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel